The shares are listed on the Nasdaq Global Market

Davis Polk advised the sales agents in connection with the SEC-registered at-the-market offering by Personalis, Inc. of its common stock for up to an aggregate amount of $50 million. The common stock is listed on the Nasdaq Global Market under the symbol “PSNL.”

Personalis develops and markets advanced cancer genomic tests. Its tests are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies and, it expects in the near future, for clinical trial enrollment. Its tests are used by physicians to detect cancer recurrence, monitor cancer evolution and uncover insights for therapy selection. It also provides sequencing and data analysis services to support population sequencing initiatives.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Elsie Cheang and Brendon S. Brown. All members of the Davis Polk team are based in the Northern California office.

Copy link to share post